Addex (ADXN) Director Jason Nunn Exercises Options, Receives 219,561 Shares

What Happened

• Jason Raleigh Nunn, a director of Addex Therapeutics Ltd. (ADXN), reported option-related transactions on Sep 2, 2026 that resulted in the acquisition of 219,561 common shares and the adjustment of 50,000 derivative units.
• The filing shows $0 cash reported for the transactions; footnotes explain these shares were issued following option exercises and a Remuneration Committee decision that reduced the strike/exercise price of the affected units to $0.032 per share (USD equivalent). The reported USD strike prices reflect conversion from CHF at a rate of $1.2296 per CHF 1.00.

Key Details

• Transaction date: September 2, 2026.
• Primary movement: Acquisition of 219,561 common shares (result of option exercise / deferred strike payment plan adjustments). Also shows disposition/acquisition entries for 50,000 derivative units tied to the repricing.
• Price: Strike/exercise price repriced to $0.032 per share (USD conversion noted in filing); filing reports aggregate cash amounts as $0 under reporting conventions.
• Footnotes: F1–F3 explain (1) the 219,561 shares arose from earlier option grants (128,238 from Oct 26, 2022 and 91,323 from Nov 27, 2023) and were affected by the deferred strike price payment plan, (2) the exercise prices were repriced to $0.032 per share effective Sep 2, 2026, and (3) USD amounts reflect CHF→USD conversion at 1.2296. Transactions were reported as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act as applicable.
• Shares owned after transaction: Not disclosed in the Form 4 provided.
• Timeliness: Filed Sep 4, 2026 for a Sep 2, 2026 transaction — filing appears timely (not marked late).

Context

• These were option exercises / repricing adjustments rather than open-market purchases or sales; no open-market sale of the acquired shares is reported.
• Disposition-to-issuer entries in this filing reflect internal mechanics of the exercise and deferred payment plan as explained in the footnotes; they do not necessarily indicate a public sale.
• The transaction is informational for investors tracking insider holdings and option repricings; it is not an explicit statement of intent or market timing by the insider.